Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 19, 2016

View Archived Issues

OncoImmune, Pfizer enter agreement for anti-CTLA-4 monoclonal antibody

Inhibition of midkine as promising new therapeutic strategy to enhance osteoporotic fracture healing

DR6-mediated necroptotic signaling pathways as targets for antimetastatic therapies

RSV F Vaccine does not meet efficacy endpoints in phase III trial in older adults

Johnson & Johnson to acquire Abbott Medical Optics

EMA's CHMP recommends approval of Glyxambi for adults with type 2 diabetes

Retrotope's phase I/II study of RT-001 meets all primary goals

EMA committee recommends E.U. approval of Stelara for moderate to severely active Crohn's disease

Novel mutations found that may cause Wolcott-Rallison syndrome

Topivert initiates phase IIa trial of TOP-1288 in ulcerative colitis

EMA committee recommends approval of Parsabiv in E.U.

New company GammaDelta Therapeutics raises seed funding

Kyowa Kirin initiates first-in-human trial of KHK-2455

NBAS mutations may cause new syndrome associated with type 1 diabetes

EMA committee grants positive opinion for conditional approval of Ninlaro

Dosing begins in Zymeworks' phase I study of ZW-25

Asterias Biotherapeutics reports positive results of AST-OPC1 spinal cord injury trials

TeneoBio obtains license to Ligand Pharmaceuticals' OmniFlic technology

Confirmatory phase III study of PF-06438179 meets primary endpoint

Dr. Reddy's Laboratories and Amgen expand collaboration

Lion Biotechnologies enters two agreements regarding TIL products

GX-H9 shows potential for the treatment of AGHD

Pfizer receives positive CHMP opinion for Ibrance in Europe

MRC-Industry Asset Sharing Initiative makes deprioritized compounds available to researchers

Weekly somapacitan appears more convenient than daily human growth hormone in phase III trial

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...